Five things to watch in markets in the week ahead
Casdin Partners, a group that includes beneficial owners and entities related to Eli Casdin, reported purchasing shares of Standard BioTools INC (NASDAQ:LAB) between November 7 and November 12, 2025. The purchases totaled $1.37 million, with prices ranging from $1.1234 to $1.196 per share. The $455.7 million market cap company is currently trading near InvestingPro’s Fair Value assessment, with a current price of $1.18.
The transactions involved the acquisition of 225,000 shares on November 7, 275,000 shares on November 10, 300,000 shares on November 11, and 375,000 shares on November 12. These purchases come as Standard BioTools maintains a strong liquidity position with a current ratio of 4.38, holding more cash than debt on its balance sheet, though the company is quickly burning through cash.
Following these transactions, the total shares owned by Casdin Partners Master Fund, L.P. is 62,050,000. Eli Casdin directly owns 2,901,062 shares. Casdin Private Growth Equity Fund II, L.P. owns 13,939,637 shares, and Casdin Private Growth Equity Fund, L.P. holds 2,744,219 shares. Analysts have set price targets between $1.55 and $1.75 for LAB, which currently has an overall financial health rating of "FAIR" according to InvestingPro, which offers 7 additional ProTips and a comprehensive Pro Research Report on this stock.
In other recent news, Standard BioTools Inc. has announced a significant restructuring plan aimed at improving operational efficiency and aligning costs with revenue projections. The company plans to reduce its global workforce by about 15%, incurring approximately $7.5 million in expenses related to severance and termination benefits. This move is expected to be financially managed over the coming months. Additionally, Standard BioTools will consolidate its research and development operations from South San Francisco to its Singapore facility, further impacting its U.S. workforce, including management positions. This consolidation will result in an additional $3.6 million in restructuring costs, with $0.9 million attributed to non-cash expenses from share-based awards. The company has indicated that these financial estimates are subject to change based on various assumptions and future developments. These recent developments reflect Standard BioTools’ strategic efforts to streamline operations and manage expenses effectively.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.